Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory virus that
gains entry via angiotensin-converting enzyme 2 (ACE2) within airway epithelium. Patients …

As a broad-spectrum antiviral nanoparticle, the cell membrane nanodecoy is a promising
strategy for preventing viral infections. However, most of the cell membrane nanodecoys can …

SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced
neutralization against variants raises questions as to whether other antibody functions are …

Administration of neutralizing antibodies (nAbs) has proved to be effective by providing
immediate protection against SARS‐CoV‐2. However, dual strategies combining virus …

Background The emergence of the coronavirus disease 2019 (COVID-19) pandemic and the
new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern …

Development of highly effective antivirals that are robust to viral evolution is a practical
strategy for combating the continuously evolved severe acute respiratory syndrome …

Patients with rheumatic diseases (RD) are considered to be a high-risk population for
infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The …

Although the global crisis caused by the coronavirus disease 2019 (COVID-19) pandemic is
over, the global epidemic of the disease continues. Severe acute respiratory syndrome …

Monoclonal antibodies are considered to be highly effective therapeutic tools for the
treatment of mild to moderate COVID-19 patients. In the present work, we describe the …

The devastating COVID-19 pandemic motivates the development of safe and effective
antivirals to reduce morbidity and mortality associated with infection. We developed …